Your browser doesn't support javascript.
loading
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors.
Fried, William; Tyagi, Mrityunjay; Minakhin, Leonid; Chandramouly, Gurushankar; Tredinnick, Taylor; Ramanjulu, Mercy; Auerbacher, William; Calbert, Marissa; Rusanov, Timur; Hoang, Trung; Borisonnik, Nikita; Betsch, Robert; Krais, John J; Wang, Yifan; Vekariya, Umeshkumar M; Gordon, John; Morton, George; Kent, Tatiana; Skorski, Tomasz; Johnson, Neil; Childers, Wayne; Chen, Xiaojiang S; Pomerantz, Richard T.
Afiliación
  • Fried W; Molecular and Computational Biology, Department of Biological Sciences and Chemistry, University of Southern California, Los Angeles, CA, USA.
  • Tyagi M; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Minakhin L; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Chandramouly G; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Tredinnick T; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Ramanjulu M; Recombination Therapeutics, Pennsylvania Biotechnology Center, Doylestown, PA, 18902, USA.
  • Auerbacher W; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Calbert M; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Rusanov T; Fels Cancer Institute for Personalized Medicine, Philadelphia, PA, USA.
  • Hoang T; Department of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
  • Borisonnik N; Janssen Biotech, Malvern, PA, 19355, USA.
  • Betsch R; Polysciences, Inc., Huntingdon Valley, PA, USA.
  • Krais JJ; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
  • Wang Y; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
  • Vekariya UM; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
  • Gordon J; Fels Cancer Institute for Personalized Medicine, Philadelphia, PA, USA.
  • Morton G; Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
  • Kent T; Fels Cancer Institute for Personalized Medicine, Philadelphia, PA, USA.
  • Skorski T; Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, PA, USA.
  • Johnson N; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Childers W; Fels Cancer Institute for Personalized Medicine, Philadelphia, PA, USA.
  • Chen XS; Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
  • Pomerantz RT; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Nat Commun ; 15(1): 2862, 2024 Apr 05.
Article en En | MEDLINE | ID: mdl-38580648
ABSTRACT
The DNA damage response (DDR) protein DNA Polymerase θ (Polθ) is synthetic lethal with homologous recombination (HR) factors and is therefore a promising drug target in BRCA1/2 mutant cancers. We discover an allosteric Polθ inhibitor (Polθi) class with 4-6 nM IC50 that selectively kills HR-deficient cells and acts synergistically with PARP inhibitors (PARPi) in multiple genetic backgrounds. X-ray crystallography and biochemistry reveal that Polθi selectively inhibits Polθ polymerase (Polθ-pol) in the closed conformation on B-form DNA/DNA via an induced fit mechanism. In contrast, Polθi fails to inhibit Polθ-pol catalytic activity on A-form DNA/RNA in which the enzyme binds in the open configuration. Remarkably, Polθi binding to the Polθ-polDNA/DNA closed complex traps the polymerase on DNA for more than forty minutes which elucidates the inhibitory mechanism of action. These data reveal a unique small-molecule DNA polymeraseDNA trapping mechanism that induces synthetic lethality in HR-deficient cells and potentiates the activity of PARPi.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína BRCA1 / Inhibidores de Poli(ADP-Ribosa) Polimerasas Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína BRCA1 / Inhibidores de Poli(ADP-Ribosa) Polimerasas Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos